The Impact of the GOLD 2023 on Clinical Treatment in Northeast China

Click to increase image sizeClick to decrease image size

Conference Presentation

The manuscript has not been and will not be submitted, in part or entirety, elsewhere for publication. There are no other submissions or publications that include material that is largely duplicative of that presented in the manuscript or derived from the same subjects.

Data Sharing Statement

The datasets used and analyzed in this study are available from the corresponding author upon reasonable request.

Ethics Statement

This study was approved by the Institutional Review Board of China Medical University ([2018]083), and all subjects gave informed consent to this study. This study was conducted in accordance with the Declaration of Helsinki.

Acknowledgments

The authors would like to thank all the participants and all investigators from the First Hospital of China Medical University, Central Hospital Affiliated to Shenyang Medical College, People’s Hospital of County Kangping, Tieling County Central Hospital, People’s Hospital of Xinmin, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group, The Fourth Affiliated Hospital of Harbin Medical University, Liaoyang County Central Hospital, and People’s Hospital of County Yixian for their support of this study.

Disclosure

The authors report no competing interests in this work.

Additional information

Funding

This study was funded by the Key Laboratory of Respiratory Diseases in Liaoning Province and the National Key R&D Program of China (Grant #2018YFC1311600).